Outcomes of HIV positive patients with Cryptococcal meningitis in the absence of optimal treatment: Experience from single institution in Mexico

Abstract:

Background: In Mexico, as in other countries the treatment of Cryptococcal meningitis (CM) is limited primarily by the high costs and availability of first line drugs. In our country, Liposomal Amphotericin B is prohibitively expensive for the general population and flucytosine is not available. Additionally, in recent years there has been a widespread lack of Amphotericin b deoxycholate (AmBd), which has forced clinicians to use high doses of Fluconazole (FLU) or other alternative options. The outcomes of these alternative antifungal schemes have not been addressed. Methods & Materials: We retrospectively reviewed cases of patients with diagnosis of Human Immunodeficiency Virus (HIV) infection and CM in our hospital from June 2010 to September 2017. Measures of central tendency, rates and relative risk were calculated. Stratification was performed based on the treatment used and its outcome at 30 days. Results …

Año de publicación:

2018

Keywords:

Fuente:

google